Biosensors International Group, Ltd. develops,
manufactures and markets innovative medical devices,
aiming to improve patients’ lives through pioneering
medical technology that pushes forward the boundaries
of innovation. Founded in 1990, we were listed on the
Mainboard of the Singapore Stock Exchange in 2005.
The Group currently operates through four business
units (“BU”): the Cardiovascular BU, composed
primarily of the BioMatrix™ family of drug-eluting stents
and stent technologies such as BA9™; the Cardiac
Diagnostic BU, including Spectrum Dynamics products
that offer advanced medical imaging and clinical
solutions to help interventional cardiologists determine
the most appropriate treatment for patients; the
Peripheral Intervention BU, offering solutions for the
treatment of patients with peripheral arterial disease;
and the Critical Care Products BU.
The Group has operations worldwide and is
headquartered in Singapore.